Clinical Trial Readiness for Spinal Muscular Atrophy: Experience of an International Educational-Training Initiative.

Spinal muscular atrophy clinical trial readiness education and training therapeutic advances

Journal

Journal of neuromuscular diseases
ISSN: 2214-3602
Titre abrégé: J Neuromuscul Dis
Pays: Netherlands
ID NLM: 101649948

Informations de publication

Date de publication:
2022
Historique:
pubmed: 1 11 2022
medline: 16 11 2022
entrez: 31 10 2022
Statut: ppublish

Résumé

Several successful clinical trials have been conducted in spinal muscular atrophy (SMA) over recent years which have led to the approval of splicing modifiers and gene transfer therapies. With an increasing number of other agents progressing through pre-clinical and clinical development, increasing worldwide clinical trial readiness is becoming essential.SMA Europe initiated a clinical trial readiness project, which included the development of a pilot face-to-face educational-training initiative for clinical specialists and physiotherapists involved in SMA, with an emphasis on the patient perspective. Participants were selected through two surveys and, ahead of the meeting, a mock protocol with specific questions was provided. The initiative involved a series of presentations, role-play and interactive exercises. We describe here our experience and evaluation of this educational-training initiative, emphasising scientific aspects, psychosocial implications and level of satisfaction.From a participant, patient and industry perspective, such training was considered successful and met the objective, which was to improve clinical trial readiness in emerging sites. Resource planning, ethical considerations and communication with patients were identified as three important topics for future training. This initiative highlights the need to develop a training programme to achieve clinical trial readiness across Europe and showcases a collaborative effort with different stakeholders, clinicians, patient advocacy groups and sponsors to address an important issue.

Identifiants

pubmed: 36314215
pii: JND221538
doi: 10.3233/JND-221538
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

809-820

Auteurs

Eduardo F Tizzano (EF)

Department of Clinical and Molecular Genetics Hospital Vall d'Hebron, and Medicine Genetics Group, Vall d'Hebron Research Institute (VHIR), 08035 Barcelona, Spain.

Vanessa Christie-Brown (V)

Research Programme Manager, SMA Europe e.V., Freiburg, Germany.

Giovanni Baranello (G)

The Dubowitz Neuromuscular Centre, NIHR Great Ormond Street Hospital Biomedical Research Centre, Great Ormond Street Institute of Child Health University College London, & Great Ormond Street Hospital NHS Foundation Trust, London, UK.

Olga Germanenko (O)

Patient Representative, Head of SMA Family Foundation Russia & Delegate of SMA Europe e. V., Freiburg, Germany.

Allyson Gray (A)

Paediatric Research Nurse, Great Ormond Street Hospital NHS Trust, London, United Kingdom.

Marija Krstic (M)

Patient Representative, SMA Serbia & Delegate of SMA Europe e.V., Freiburg, Germany.

Charlotte Lilien (C)

MPT: MDUK Oxford Neuromuscular Centre, Oxford, United Kingdom.

Hinal Patel (H)

The Dubowitz Neuromuscular Centre, NIHR Great Ormond Street Hospital Biomedical Research Centre, Great Ormond Street Institute of Child Health University College London, & Great Ormond Street Hospital NHS Foundation Trust, London, UK.

Laurent Servais (L)

MDUK Oxford Neuromuscular Centre, Department of Paediatrics, University of Oxford.

Mariacristina Scoto (M)

The Dubowitz Neuromuscular Centre, Great Ormond Street Hospital NHS Foundation Trust, London, UK & NIHR Great Ormond Street Hospital Biomedical Research Centre, Great Ormond Street Institute of Child Health University College London.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH